Originally published as JCO Early Release 10.1200/JCO.2002.11.061 on July 29 2002
Journal of Clinical Oncology, Vol 20, Issue 18
(September), 2002: 3792-3803
© 2002 American Society for Clinical Oncology
Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
By Roy S. Herbst,
Kenneth R. Hess,
Hai T. Tran,
Jennifer E. Tseng,
Nizar A. Mullani,
Chusilp Charnsangavej,
Timothy Madden,
Darren W. Davis,
David J. McConkey,
Michael S. O’Reilly,
Lee M. Ellis,
James Pluda,
Waun K. Hong,
James L. Abbruzzese
From the Departments of Thoracic and Head and Neck Medical Oncology, Biostatistics, Diagnostic Radiology, Pharmaceutical Sciences, Cancer Biology, Radiation Oncology, Surgical Oncology, and Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, and University of Texas Houston Health Science Center, Houston, TX, and National Cancer Institute, Bethesda, MD.
Address reprint requests to Roy S. Herbst, MD, PhD, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030.
PURPOSE: Endostatin, a 20-kd fragment of collagen XVIII, is a potent inhibitor of angiogenesis. We evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tumors.
PATIENTS AND METHODS: Twenty-six patients were enrolled onto a dose-finding trial of rh-Endo administered as an intravenous bolus over a 20-minute period once daily. Three patients each were treated at dose levels of 15, 30, 60, 120, 180, and 600 mg/m2/d, and seven patients were treated at 300 mg/m2/d. Treatment consisted of a minimum of two 28-day cycles. Evaluations included noninvasive imaging, pharmacokinetics, and serum biomarkers.
RESULTS: Twenty-five patients were treated with rh-Endo. Treatment was well tolerated; there were no dose-limiting toxic effects. Bacteremia from frequent central line access was the most common problem. The pharmacokinetic disposition of rh-Endo was linear and best described using a two-compartmental open model. The overall mean half-life was 10.7 ± 4.1 hours. A dose of 300 mg/m2 achieved an area under the concentration-time curve associated with activity in preclinical models. In two patients, there was evidence of antitumor activity, but no responses were seen. Serum markers of angiogenic activity did not provide insight into rh-Endo’s activity. Serum antibodies were observed against both rh-Endo and the Pichia pastoris vector, but no allergic reactions were observed.
CONCLUSION: rh-Endo was safe and well tolerated. rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with activity in preclinical models. Evidence of minor antitumor activity was observed and further studies are indicated.
Presented in part at the Thirty-Seventy Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.
This article was published ahead of print at www.jco.org.
This article has been cited by other articles:
|
|
|
|
 
B. Ng, J. Zakrzewski, M. Warycha, P. J. Christos, D. F. Bajorin, R. L. Shapiro, R. S. Berman, A. C. Pavlick, D. Polsky, M. Mazumdar, et al.
Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients
Clin. Cancer Res.,
October 1, 2008;
14(19):
6253 - 6258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tan, S. Yang, Y. Feng, C. Liu, J. Cao, G. Mu, and F. Wang
Characterization and Secondary Structure Analysis of Endostatin Covalently Modified by Polyethylene Glycol and Low Molecular Weight Heparin
J. Biochem.,
August 1, 2008;
144(2):
207 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. A. Mullani, R. S. Herbst, R. G. O'Neil, K. L. Gould, B. J. Barron, and J. L. Abbruzzese
Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow
J. Nucl. Med.,
April 1, 2008;
49(4):
517 - 523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Blood,
October 15, 2007;
110(8):
2899 - 2906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
J. Dent. Res.,
October 1, 2007;
86(10):
927 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi
Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin
Clin. Cancer Res.,
July 1, 2007;
13(13):
3968 - 3976.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Isayeva, D. Chanda, L. Kallman, I.-E. A. Eltoum, and S. Ponnazhagan
Effects of Sustained Antiangiogenic Therapy in Multistage Prostate Cancer in TRAMP Model
Cancer Res.,
June 15, 2007;
67(12):
5789 - 5797.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kogelberg, B. Tolner, S. K. Sharma, M. W Lowdell, U. Qureshi, M. Robson, T. Hillyer, R. B. Pedley, W. Vervecken, R. Contreras, et al.
Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy
Glycobiology,
January 1, 2007;
17(1):
36 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mayer, R. J. Francis, S. K. Sharma, B. Tolner, C. J. Springer, J. Martin, G. M. Boxer, J. Bell, A. J. Green, J. A. Hartley, et al.
A Phase I Study of Single Administration of Antibody-Directed Enzyme Prodrug Therapy with the Recombinant Anti-Carcinoembryonic Antigen Antibody-Enzyme Fusion Protein MFECP1 and a Bis-Iodo Phenol Mustard Prodrug.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6509 - 6516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Schaffhauser, T. Veikkola, K. Strittmatter, H. Antoniadis, K. Alitalo, and G. Christofori
Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice
J. Leukoc. Biol.,
October 1, 2006;
80(4):
669 - 676.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. C.M. Martinico, S. Jezzard, N. J. H. Sturt, G. Michils, S. Tejpar, R. K. Phillips, and G. Vassaux
Assessment of Endostatin Gene Therapy for Familial Adenomatous Polyposis-Related Desmoid Tumors
Cancer Res.,
August 15, 2006;
66(16):
8233 - 8240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al.
Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors
J. Clin. Oncol.,
August 1, 2006;
24(22):
3555 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Holmgren, E. Ambrosino, O. Birot, C. Tullus, N. Veitonmaki, T. Levchenko, L.-M. Carlson, P. Musiani, M. Iezzi, C. Curcio, et al.
A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth
PNAS,
June 13, 2006;
103(24):
9208 - 9213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clamp, F. H. Blackhall, A. Henrioud, G. C. Jayson, K. Javaherian, J. Esko, J. T. Gallagher, and C. L. R. Merry
The Morphogenic Properties of Oligomeric Endostatin Are Dependent on Cell Surface Heparan Sulfate
J. Biol. Chem.,
May 26, 2006;
281(21):
14813 - 14822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-P. Li, C. Y.S. Li, X. Li, Y. Ding, L. L.Y. Chan, P.-H. Yang, G. Li, X. Liu, J. S. Lin, J. Wang, et al.
Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin
Mol. Cancer Ther.,
May 1, 2006;
5(5):
1290 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Emmenegger and R. S. Kerbel
A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs
Clin. Cancer Res.,
November 1, 2005;
11(21):
7589 - 7592.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. G. Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo, and K. Hoekman
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer
Ann. Onc.,
October 1, 2005;
16(10):
1695 - 1701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hoekstra, F. Y.F.L. de Vos, F. A.L.M. Eskens, J. A. Gietema, A. van der Gaast, H. J.M. Groen, R. A. Knight, R. A. Carr, R. A. Humerickhouse, J. Verweij, et al.
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer
J. Clin. Oncol.,
August 1, 2005;
23(22):
5188 - 5197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-M. Cho, J. D. Rosenblatt, Y.-S. Kang, M. L. Iruela-Arispe, S. L. Morrison, M. L. Penichet, Y.-G. Kwon, T.-W. Kim, K. A. Webster, H. Nechustan, et al.
Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein
Mol. Cancer Ther.,
June 1, 2005;
4(6):
956 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gasparini, R. Longo, M. Fanelli, and B. A. Teicher
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
J. Clin. Oncol.,
February 20, 2005;
23(6):
1295 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kirsch, P. Weigel, T. Pinzer, R. S. Carroll, P. McL. Black, H.-K. Schackert, and G. Schackert
Therapy of Hematogenous Melanoma Brain Metastases with Endostatin
Clin. Cancer Res.,
February 1, 2005;
11(3):
1259 - 1267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K. Skovseth, M. J. T. Veuger, D. R. Sorensen, P. M. De Angelis, and G. Haraldsen
Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo
Blood,
February 1, 2005;
105(3):
1044 - 1051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. B. G. Gebbink, E. E. Voest, and A. Reijerkerk
Do antiangiogenic protein fragments have amyloid properties?
Blood,
September 15, 2004;
104(6):
1601 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Yoon, N. H. Segal, A. B. Olshen, M. F. Brennan, and S. Singer
Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma
Ann. Onc.,
August 1, 2004;
15(8):
1261 - 1266.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Korn
Nontoxicity Endpoints in Phase I Trial Designs for Targeted, Non-Cytotoxic Agents
J Natl Cancer Inst,
July 7, 2004;
96(13):
977 - 978.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Parulekar and E. A. Eisenhauer
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
J Natl Cancer Inst,
July 7, 2004;
96(13):
990 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Panchal, J. Rehman, A. T. Nguyen, J. W. Brown, M. W. Turrentine, Y. Mahomed, and K. L. March
Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease
J. Am. Coll. Cardiol.,
April 21, 2004;
43(8):
1383 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ponnazhagan, G. Mahendra, S. Kumar, D. R. Shaw, C. R. Stockard, W. E. Grizzle, and S. Meleth
Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy: Long-Term Efficacy of a Vector Encoding Angiostatin and Endostatin over Vectors Encoding a Single Factor
Cancer Res.,
March 1, 2004;
64(5):
1781 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer, and R. L. Comis
Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
Clin. Cancer Res.,
February 15, 2004;
10(4):
1206 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Wahl, T. L. Moser, and S. V. Pizzo
Angiostatin and Anti-angiogenic Therapy in Human Disease
Recent Prog. Horm. Res.,
January 1, 2004;
59(1):
73 - 104.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. W. Davis, Y. Shen, N. A. Mullani, S. Wen, R. S. Herbst, M. O'Reilly, J. L. Abbruzzese, and D. J. McConkey
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors
Clin. Cancer Res.,
January 1, 2004;
10(1):
33 - 42.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al.
Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects
Cancer Res.,
December 15, 2003;
63(24):
8890 - 8898.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Daly, A. Makris, M. Reed, and C. E. Lewis
Hemostatic Regulators of Tumor Angiogenesis: A Source of Antiangiogenic Agents for Cancer Treatment?
J Natl Cancer Inst,
November 19, 2003;
95(22):
1660 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-T. Le and A. J. Giaccia
Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer
Clin. Cancer Res.,
October 1, 2003;
9(12):
4287 - 4295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Plum, A. D. Hanson, K. M. Volker, H. A. Vu, B. K. L. Sim, W. E. Fogler, and A. H. Fortier
Synergistic Activity of Recombinant Human Endostatin in Combination with Adriamycin: Analysis of in Vitro Activity on Endothelial Cells and in Vivo Tumor Progression in an Orthotopic Murine Mammary Carcinoma Model
Clin. Cancer Res.,
October 1, 2003;
9(12):
4619 - 4626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Collins
Functional Imaging in Phase I Studies: Decorations or Decision Making?
J. Clin. Oncol.,
August 1, 2003;
21(15):
2807 - 2809.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Reijerkerk, L. O. Mosnier, O. Kranenburg, B. N. Bouma, P. Carmeliet, T. Drixler, J. C.M. Meijers, E. E. Voest, and M. F.B.G. Gebbink
Amyloid Endostatin Induces Endothelial Cell Detachment by Stimulation of the Plasminogen Activation System
Mol. Cancer Res.,
June 1, 2003;
1(8):
561 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. M. Schellens and M. J. Ratain
Endostatin: Are the 2 Years Up Yet?
J. Clin. Oncol.,
September 15, 2002;
20(18):
3758 - 3760.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. K. Daugherty
The "Cure" for Cancer: Can the Media Report the Hope Without the Hype?
J. Clin. Oncol.,
September 15, 2002;
20(18):
3761 - 3764.
[Full Text]
[PDF]
|
|
|
|
